HomeAI · summaries
Storia in 4 fonti
Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease
The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults | India News
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer
India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee…
- ·
thehindubusinessline.com
Novo Nordisk’s obesity drug Wegovy gets CDSCO approval to treat liver condition
Novo Nordisk's Wegovy receives CDSCO approval as India's first GLP-1 treatment for fatty liver disease, addressing rising health concerns.
- ·
hindustantimes.com
Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease
The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults |…
- ·
thehindu.com
India approves Novo Nordisk’s weight loss drug Wegovy for fatty liver disease
The Central Drugs Standard Control Organization (CDSCO) has approved Danish major Novo Nordisk’s weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication —…